Skip to content
Evigrade
MajorMacrolide antibiotic×Class III antiarrhythmic, selective IKr blocker

Updated · Methodology

Mechanism

Dofetilide is a class III antiarrhythmic. It blocks the rapid component of the delayed rectifier potassium current (IKr), and QT prolongation depends directly on its plasma concentration (dofetilide label, US Food and Drug Administration, FDA). Clarithromycin itself prolongs the QT interval and can cause torsade de pointes (clarithromycin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; clarithromycin FDA label), so the effects of the two drugs on QT may add up. Clarithromycin is a strong inhibitor of the CYP3A4 enzyme and also inhibits the transporter P-glycoprotein (P-gp) (AEMPS, FDA). CYP3A4 metabolises a small part of dofetilide, and the US dofetilide label lists macrolides among the CYP3A4 inhibitors that can increase dofetilide levels (dofetilide FDA label). The kidneys are the main route of dofetilide elimination: about 80% of a dose leaves the body in the urine, mostly unchanged. The documents do not state how much clarithromycin changes dofetilide levels (dofetilide FDA label).

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). The Medication Guide of the US dofetilide label lists the warning signs of a dangerous arrhythmia: feeling faint, dizziness and a fast heartbeat. It warns that torsade de pointes can lead to death (dofetilide label, US Food and Drug Administration, FDA). In people with supraventricular arrhythmias who took dofetilide, torsade de pointes occurred in 0.8%, mostly within the first three days of treatment. Low potassium or magnesium increases the risk (FDA). Clarithromycin has been associated with QT prolongation and infrequent cases of arrhythmia. Torsade de pointes and deaths have been reported, including torsade de pointes when clarithromycin was combined with the antiarrhythmics quinidine and disopyramide (clarithromycin FDA label).

Management

Avoid the combination. The US clarithromycin label says to avoid clarithromycin in patients receiving drugs known to prolong the QT interval and in those receiving class IA or class III antiarrhythmics, including dofetilide. Its interaction table marks the combination with dofetilide as not recommended (clarithromycin label, US Food and Drug Administration, FDA). The US dofetilide label does not recommend dofetilide with other drugs that prolong the QT interval and names certain oral macrolides among them. It advises caution when combining dofetilide with CYP3A4 inhibitors, including macrolides (dofetilide FDA label). The Spanish clarithromycin summary of product characteristics (SmPC) contraindicates clarithromycin only with named QT-prolonging drugs (astemizole, cisapride, domperidone, pimozide, terfenadine) and advises caution with other such drugs (clarithromycin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dofetilide is not in the Spanish medicines register CIMA. If dofetilide is stopped so that a potentially interacting drug can be given, wait at least two days before starting that drug. When restarting dofetilide, keep the patient for at least three days in a facility that can calculate creatinine clearance, provide continuous electrocardiogram (ECG) monitoring and perform cardiac resuscitation (FDA). Dofetilide is contraindicated if the QT or heart-rate-corrected QT interval (QTc) is above 440 ms (500 ms with ventricular conduction abnormalities). Stop dofetilide if the QTc exceeds 500 ms (550 ms with such abnormalities). Keep potassium in the normal range before and during treatment (FDA). Clarithromycin is contraindicated in people with a history of QT prolongation, ventricular arrhythmia or torsade de pointes, and in those with low potassium or magnesium (AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Clarithromycin

Other interactions with Dofetilide